Peter Öhman
AstraZeneca
32 Papers
113 Citations
Peter Öhman is an academic researcher from AstraZeneca. The author has contributed to research in topics: Exenatide & Medicine. The author has an hindex of 18, co-authored 32 publications. Previous affiliations of Peter Öhman include Durham University & Duke University.
Chat about Author
Papers
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica,Deepak L. Bhatt,Deepak L. Bhatt,Eugene Braunwald,P. Gabriel Steg,Jaime A. Davidson,Boaz Hirshberg,Peter Öhman,Robert Frederich,Stephen D. Wiviott,Elaine B. Hoffman,Matthew A. Cavender,Jacob A. Udell,Nihar R. Desai,Ofri Mosenzon,Darren K. McGuire,Kausik K. Ray,Lawrence A. Leiter,Itamar Raz +18 more
TL;DR: Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes, and DPP-4 inhibition with saxgliptin did not increase or decrease the rate of ischemic events, though the rates of hospitalization for heart failure was increased.
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R. Holman,M. Angelyn Bethel,Robert J. Mentz,Vivian P. Thompson,Yuliya Lokhnygina,John B. Buse,Juliana C.N. Chan,Jasmine Choi,Stephanie M. Gustavson,Nayyar Iqbal,Aldo P. Maggioni,Steven P. Marso,Peter Öhman,Neha J. Pagidipati,Neil Poulter,Ambady Ramachandran,Bernard Zinman,Adrian F. Hernandez +17 more
TL;DR: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo.
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
M. Angelyn Bethel,Rishi A Patel,Peter Merrill,Yuliya Lokhnygina,John B. Buse,Robert J. Mentz,Neha J. Pagidipati,Juliana C.N. Chan,Stephanie M. Gustavson,Nayyar Iqbal,Aldo P. Maggioni,Peter Öhman,Neil Poulter,Ambady Ramachandran,Bernard Zinman,Bernard Zinman,Adrian F. Hernandez,Rury R. Holman +17 more
TL;DR: Overall cardiovascular safety across all GLP-1 receptor agonist cardiovascular outcome trials is shown and drugs in this class can reduce three-point major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality risk, albeit to varying degrees for individual drugs, without significant safety concerns.
527
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
TL;DR: Exenatide plus dapagliflozin was significantly superior to either drug alone for all secondary efficacy endpoints, with greater reductions in fasting plasma and postprandial glucose, more patients with an HbA1c less than 7·0%.
369
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
Rury R. Holman,M A Bethel,Jyothis T. George,Harald Sourij,Zoë Doran,Joanne F. Keenan,Nardev S. Khurmi,Robert J. Mentz,Abderrahim Oulhaj,John B. Buse,Juliana C.N. Chan,Nayyar Iqbal,Sudeep Kundu,Aldo P. Maggioni,Steven P. Marso,Peter Öhman,Michael J. Pencina,Neil R Poulter,Lisa Porter,Ambady Ramachandran,Bernard Zinman,Adrian F. Hernandez +21 more
TL;DR: Whether exenatide once-weekly can reduce cardiovascular events in patients with T2DM with a broad range of cardiovascular risk over approximately 5 years is assessed.
102